
BENZONATATE- benzonatate capsule A-S Medication Solutions

Benzonatate Capsules, USP

DESCRIPTION

Benzonatate capsules, USP, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26- onaoxaoctacosan-28-ylp-(butylamino) benzoate; with a molecular weight of 603.7.



C30H53NO11

Each benzonatate capsules, USP for oral administration contains 100 mg or 200 mg benzonatate, USP. In addition, each capsule contains the following inactive ingredients: D&C Yellow #10, gelatin, glycerin, lecithin, light mineral oil, propylene glycol, purified water, shellac glaze, titanium dioxide, and white edible ink.

CLINICAL PHARMACOLOGY

Benzonatate capsules act peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate capsules have no inhibitory effect on the respiratory center in recommended dosage.

INDICATIONS AND USAGE

Benzonatate capsules, USP are indicated for the symptomatic relief of cough.

CONTRAINDICATIONS

Hypersensitivity to benzonatate or related compounds.

WARNINGS

Hypersensitivity

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe

reactions have required intervention with vasopressor agents and supportive measures.

Psychiatric Effects

Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate capsules in combination with other prescribed drugs.

Accidental Ingestion and Death in Children

Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see **OVERDOSAGE**).

PRECAUTIONS

Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Information for Patients:

Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush benzonatate capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

Keep benzonatate capsules out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.

Overdosage resulting in death may occur in adults.

Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of benzonatate capsules, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate capsules at one time.

Usage in Pregnancy

PREGNANCY CATEGORY C

Animal reproduction studies have not been conducted with benzonatate capsules. It is also not known whether benzonatate capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate capsules should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate capsules are administered to a nursing woman.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate capsules.

Pediatric Use

Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

ADVERSE REACTIONS

Potential Adverse Reactions to benzonatate capsules may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS

sedation; headache; dizziness; mental confusion; visual hallucinations.

GI

constipation; nausea; GI upset.

Dermatologic

pruritus; skin eruptions.

Other

nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity.

Deliberate or accidental overdose has resulted in death, particularly in children.

Hypersensitivity reactions

including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

OVERDOSAGE

Intentional and unintentional overdose may result in death, particularly in children.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms

The signs and symptoms of overdose of benzonatate capsules have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.

CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

Treatment

In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

DOSAGE AND ADMINISTRATION

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. **Benzonatate capsules should be swallowed whole.** Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed.

HOW SUPPLIED

Product: 50090-5409 NDC: 50090-5409-0 20 CAPSULE in a BOTTLE NDC: 50090-5409-1 24 CAPSULE in a BOTTLE NDC: 50090-5409-2 30 CAPSULE in a BOTTLE NDC: 50090-5409-5 15 CAPSULE in a BOTTLE

BENZONATATE CAPSULE

Pro		No.	409	91-0
	ZONA	TATE		
	SOFTGEL (
	E AT 68 TECT FRO			•
20	CAPS	ULES	5	=
	GES BY: Medicatio		ACKAGE IN 00905409 005	RX ONLY
SOUR	CE NDC:	42806 -	714-01	=

Contains

benzonatate capsule Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:50090-5409(NDC:4 714) Route of Administration ORAL V V V Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength	BENZONATATE							
Product Information HUMAN PRESCRIPTION DRUG NDC: 50090-5409(NDC: 474) Route of Administration ORAL NDC: 50090-5409(NDC: 474) Active Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Active Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Active Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Active Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Ingredient/Active Ingredient/Active Wolety NDC: 50090-5409(NDC: 474) Ingredient/Active Ingredients NDC: 50090 Ingredient Name Strength BeNZONATATE (UNII: 5940H56ENR) (BENZONATATE - UNII: 5940H56ENR) BENZONATATE - UNII: 500 ME2) Ingredients Ingredient Name Strength GeLATIN, UNSPECIFIED (UNII: 2686QN327L) Ingredient Name Ingredient Name GeLATIN, NOSPEAN (UNII: 10156QDME2) Ingredient Name Ingredient Name Ingredient Name Ingredient Name Ingredient Name PROPYLENE GLYCOL (UNII: 15FX97QVP) Ingredient Name Ingredient Name <								
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC::50090-5409(NDC:4714) Route of Administration ORAL NDC::50090-5409(NDC:4714) NDC::50090-5409(NDC:4714) Active Ingredient/Active Wolety Ingredient Name Basis of Strength Str Benzonatate (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:SP4DHS6ENR) BENZONATATE 100 Inactive Ingredients Ingredient Name Strength Str Benzonatate (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:SP4DHS6ENR) BENZONATATE 100 Inactive Ingredients Ingredient Name Strength Str GLACTIN, UNSPECIFIED (UNII: 2686QN327L) Image: Strength Image: Strength Image: Str GLYCERIN (UNII: NOC6A3COOX) Image: Str Image: Str Image: Str Image: Str Ingredient Mineral OIL (UNII: NGK5787QVP) Image: Str Image: Str Image: Str Shellac (UNII: 46N107B710) Image: Str Image: Str Image: Str Strengt (UNII: 15FX9V2JP) Image: Str Image: Str Image: Str Str Image: Str Image: Str Image: Str Str Image: Str								
Product Type DRUG (Source) 714) Route of Administration ORAL ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Str Active Ingredient/Active Moiety Ingredient Name Basis of Strength Str BENZONATATE (UNII: 5P4DHS6ENR) (BENZ ONATATE - UNII:5P4DHS6ENR) BENZ ONATATE 100 Inactive Ingredients Ingredient Name Str D&C YELLOW NO. 10 (UNII: 355W5USQ3G) Str I GLYCERIN (UNII: PDC6A3COOX) I I I LECITHIN, SOYBEAN (UNII: IDI56QDM62) I I I IIGHT MINERAL OIL (UNII: N6K5787QVP) I I I PROPYLENE GLYCOL (UNII: 6DC91673) I I I SHELLAC (UNII: 46N1078710) I I I TITANIUM DIOXIDE (UNII: 15FK3V2JP) I I I WATER (UNII: 0590F0K00R) I I I Streage OVAL Size I I	Product Information							
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Str BENZONATATE (UNII: 5P4DHSGENR) (BENZ ONATATE - UNII:5P4DHSGENR) BENZ ONATATE 100 Inactive Ingredients BENZ ONATATE 100 Inactive Ingredients BENZ ONATATE 100 Inactive Ingredient Name Strength GLATIN, UNSPECIFIED (UNII: 2G86QN327L) GIYCERIN (UNII: PDC6A3C00X) IECITHIN, SOYBEAN (UNII: 1DI5QDM62) ILIGHT MINERAL OIL (UNII: N6K5787QVP) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) SHELLAC (UNII: 46N107B710) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) WATER (UNII: 059QF0K00R) Product Characteristics Color YELLOW Score no score Shape QVAL	Product Type							
Ingredient NameBasis of StrengthStr BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE · UNII:5P4DHS6ENR)BENZONATATE (UNII: 5P4DHS6ENR)BENZONATATE / 100Inactive IngredientsStrengthStrengthIngredient NameStrStrStrD&C YELLOW NO. 10 (UNII: 355W5USQ3G) GELATIN, UNSPECIFIED (UNII: 2G86QN327L)StrengthStrengthGLYCERIN (UNII: PDC6A3COC)StrengthStrengthJECITHIN, SOYBEAN (UNII: 1DI56QDM62)StrengthStrengthSHELLAC (UNII: 46N107B7)Strength <td>Route of Administration</td> <td>ORAL</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Route of Administration	ORAL						
Ingredient NameBasis of StrengthStr BENZONATATE (UNII: 5P4DHS6ENR) (BENZONATATE - UNII:5P4DHS6ENR)BENZONATATE (UNII: 5P4DHS6ENR)BENZONATATE (UNII: 5P4DHS6ENR)BENZONATATE (UNII: 5P4DHS6ENR)BENZONATATE (UNII: 100IngredientsIngredient NameBENZONATATE (UNII: 100IngredientsIngredient NameBENZONATATE (UNII: 100Ingredient NameStrengthStrengthD&C YELLOW NO. 10 (UNII: 355W5USQ3G)StrengthStrengthStrengthStrengthGELATIN, UNSPECIFIED (UNII: 355W5USQ3G)StrengthStrengthStrengthGELATIN, UNSPECIFIED (UNII: 355W5USQ3G)StrengthStrengthStrengthStrengthStrengthGLYCER (UNII: 1D1560DM62)StrengthStrengthStrengthStrengthStrengthStrengthSHELLAC (UNII: 46N107B7I>StrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrengthStrength <th colspan<="" td=""><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td></th>	<td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td>		-					
BENZONATATE (UNII: 5P4DHS 6ENR) (BENZONATATE - UNII:5P4DHS 6ENR) BENZONATATE (UNII: 5P4DHS 6ENR) Image: Senarging for the se	Active Ingredient/Acti	ve Moiety						
IngredientsIngredient NameStrengtD&C YELLOW NO. 10 (UNII: 355W5U5Q3G)StrengtGELATIN, UNSPECIFIED (UNII: 2G86QN327L)GGGLYCERIN (UNII: PDC6A3C0OX)GGLECITHIN, SOYBEAN (UNII: 1DI56QDM62)GGLIGHT MINERAL OIL (UNII: N6K5787QVP)GGPROPYLENE GLYCOL (UNII: 6DC9Q167V3)GGSHELLAC (UNII: 46N107B71O)GGTITANIUM DIOXIDE (UNII: 15FIX9V2JP)GGWATER (UNII: 059QF0KOOR)GGProduct CharacteristicColorYELLOWScoreShapeOVALSizeSize7mm	In	gredient Name			Bas	is of Strength	Strength	
Ingredient Name Strengt D&C YELLOW NO.10 (UNII: 355W5USQ3G) G GELATIN, UNSPECIFIED (UNII: 2686QN327L) G GLYCERIN (UNII: PDC6A3CO>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	BENZONATATE (UNII: 5P4DHS	6ENR) (BENZONATAT	E - UNII:5P4	DHS6ENR)	BENZ	ONATATE	100 mg	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G) Image: Constraint of the system of t	Inactive Ingredients							
GELATIN, UNSPECIFIED (UNI: 2G86QN327L)IdentifyGLYCERIN (UNI: PDC6A3C0>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>		Ingredient N	lame			Str	ength	
GLYCERIN (UNII: PDC6A3C00>Second State St	D&C YELLOW NO. 10 (UNII: 3	5SW5USQ3G)						
LECITHIN, SOYBEAN (UNII: IDI56QDM62)Idia (IDia (IDia))LIGHT MINERAL OIL (UNII: N6K5787QVP)Idia (IDia))PROPYLENE GLYCOL (UNII: DC9Q167V3)Idia (IDia))SHELLAC (UNII: 46N107B71)Idia (IDia))SHELLAC (UNII: 46N107B71)Idia (IDia))TITANIUM DIOXIDE (UNII: 15/15/15/15/15/15/15/15/15/15/15/15/15/1								
LIGHT MINERAL OIL (UNII: NOT STRANDED IN THE STRAND STRANDES STRAND STRAND STRAND								
PROPYLENE GLYCOL (UNI: >DC9Q167V3)Image: Section of the sec								
SHELLAC (UNII: 46N107B71) Image: Constant of the second of the secon								
TITANIUM DIOXIDE (UNII: 15/9/2JP) Image: Constant State		DC9Q167V3)						
WATER (UNII: 059QF0KO0R)Product Characterist:ColorYELLOWShapeOVALSize								
Product Characteristics Color YELLOW Score no score Shape OVAL Size 7mm								
ColorYELLOWScoreno scoreShapeOVALSize7mm								
Shape OVAL Size 7mm	Product Characteristic	cs						
	Color	YELLOW	Score			no score		
Flavor Imprint Code PC14	Shape	OVAL	Size			7mm		
	Flavor		Imprint C	Code		PC14		

Pa	ackaging				
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:50090- 5409-2	30 in 1 BOTTLE; Type 0: Not a Combination Product	12/15/2020		
2	NDC:50090- 5409-5	15 in 1 BOTTLE; Type 0: Not a Combination Product	12/15/2020		
3	NDC:50090- 5409-0	20 in 1 BOTTLE; Type 0: Not a Combination Product	12/15/2020		
4	NDC:50090- 5409-1	24 in 1 BOTTLE; Type 0: Not a Combination Product	12/15/2020		
Μ	larketing	Information			
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	

Labeler - A-S Medication Solutions (830016429)

Establishment						
Name	Address	ID/FEI	Business Operations			
A-S Medication Solutions		830016429	RELABEL(50090-5409), REPACK(50090-5409)			

Revised: 12/2023

A-S Medication Solutions